{"anticipatedPostingDate":"2009-12","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}],"title":"Stable Disease"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}],"title":"Partial Response"},{"categories":[{"measurements":[{"groupId":"OG000","value":"4"}]}],"title":"Progressive Disease"}],"denoms":[{"counts":[{"groupId":"OG000","value":"6"}],"units":"Participants"}],"description":"Stable disease in Non-Hogkin's Lymphoma = disease that does not satisfy complete (complete regression), partial (\\> or = 50% reduction) or progressive disease (increase of 25%) by at least a 4-week period. Since Acute Myelogenous Leukemia is not a solid tumor, Complete Response (CR) = \\<5% blasts with hematopoietic recovery (absolute neutrophil count \\>500) at 4 weeks.","groups":[{"description":"Patients receiving at least 12 doses of 852A.","id":"OG000","title":"852A Treatment"}],"paramType":"NUMBER","populationDescription":"Includes patients receiving at least 12 doses of 852A study drug.","reportingStatus":"POSTED","timeFrame":"Up to Week 12","title":"Number of Patients With 852A Response Using Modified Response Evaluation Criteria in Solid Tumors","type":"PRIMARY","unitOfMeasure":"Participants"}